Vaz Osborne P, Al-Islam Shofiq, Khan Zahid A, Wilde Neil, Lowe Beverley, Magilton Anna, Subar Daren A
General Surgery, East Lancashire Hospital Trust, Blackburn, GBR.
Radiology, East Lancashire Hospital Trust, Blackburn, GBR.
Cureus. 2021 Oct 27;13(10):e19075. doi: 10.7759/cureus.19075. eCollection 2021 Oct.
Management of benign biliary strictures (BBS) post bilioenteric anastomoses requires a multidisciplinary approach including surgical, radiological, and/or endoscopic input. Patients often need multiple hospital visits for treatment with the long-term possibility of restenosis. Conventionally BBS have been treated with serial percutaneous transhepatic biliary dilatations necessitating repeat procedures for drain exchange or removal. Surgery may become necessary in refractory strictures. In the last decade, there have been increasing reports of the use of biodegradable stents (BDS) in treating biliary strictures mainly to address the need for repeated procedures for drain exchange.
This study aimed to report the early outcomes in patients with BBS treated with BDS.
Retrospective analysis of prospectively collected data was performed in patients who had a bilioenteric anastomosis presenting with an anastomotic stricture and were intended to be treated with BDS. The primary endpoints reported were technical success (defined as a successful resolution of stricture on repeat cholangiogram) and clinical success (defined as the absence of repeated cholangitis). Clavien-Dindo (CD) grade of complication was reported.
Twelve patients presented with BBS and nine patients had BDS. Three patients were not considered suitable for BDS due to a non-traversable stricture and had surgery. The male-female ratio was 1:2. There was 100% technical and clinical success with one patient having stent migration not needing intervention. The procedure took an average of 45 min. In seven (77.7%) patients, it was safely performed under local anesthesia with sedation. Two patients preferred general anesthesia. There was no restenosis noted at a median follow-up of 11 months.
The use of BDS in the treatment of BBS is a safe and effective procedure. Longer-term follow-up with multi-institutional reporting on a national database is needed to assess its long-term benefits.
胆肠吻合术后良性胆管狭窄(BBS)的管理需要多学科方法,包括外科、放射学和/或内镜介入。患者通常需要多次住院治疗,且长期存在再狭窄的可能性。传统上,BBS采用经皮经肝胆道系列扩张治疗,需要重复进行引流管更换或拔除操作。对于难治性狭窄,可能需要进行手术。在过去十年中,越来越多的报告称使用可生物降解支架(BDS)治疗胆管狭窄,主要是为了满足引流管更换的重复操作需求。
本研究旨在报告使用BDS治疗BBS患者的早期结果。
对前瞻性收集的数据进行回顾性分析,这些患者因吻合口狭窄行胆肠吻合术并拟用BDS治疗。报告的主要终点为技术成功(定义为重复胆管造影显示狭窄成功解除)和临床成功(定义为无复发性胆管炎)。报告并发症的Clavien-Dindo(CD)分级。
12例患者表现为BBS,9例患者使用了BDS。3例患者因狭窄不可通过而被认为不适合使用BDS,接受了手术。男女比例为1:2。技术和临床成功率均为100%,1例患者出现支架移位但无需干预。该操作平均耗时45分钟。7例(77.7%)患者在局部麻醉加镇静下安全完成操作。2例患者选择全身麻醉。中位随访11个月时未发现再狭窄。
BDS用于治疗BBS是一种安全有效的方法。需要在国家数据库中进行多机构报告的长期随访,以评估其长期益处。